NAKO e.V. is receiving 27.8 million euros from the Federal Ministry of Research, Technology and Space (BMFTR) for the NAKO-PAIS project – an expansion of the NAKO database for research into post-infectious diseases. The project forms part of the National Decade against Post-Infectious Diseases. This ten-year initiative by the BMFTR has a total budget of 500 million euros and aims to investigate causes and disease mechanisms, as well as to develop new approaches to diagnosis and treatment. The aim is to improve care for those affected in the long term.
Gaining a better understanding of symptoms following infections
Post-acute infection syndromes (PAIS) encompass long-lasting health problems that may occur following an infection. These include Long COVID as well as other post-infectious conditions, such as myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). In this context, post-exertional malaise (PEM) – a marked worsening of existing symptoms following physical or mental exertion – is the main symptom of the ME/CFS condition.
The causes and biological mechanisms underlying these conditions are as yet poorly understood. NAKO-PAIS is now set to establish a comprehensive, long-term data resource that will enable researchers to investigate potential risk factors, disease mechanisms and the biological characteristics of resilience and recovery.
Long-term data and biological samples from NAKO
The project utilizes data and biological samples from the NAKO, Germany’s largest population-based longitudinal study. More than 205,000 people across the country are taking part in the study. The research began in 2014; further surveys took place during and after the COVID-19 pandemic and are continuing as part of the ongoing 10-year follow-up. This enables the researchers to incorporate health data from the periods before, during and after the pandemic.
“The particular strength of the funded project lies in combining the extensive data from ten years of the NAKO study with PAIS-specific questionnaires, genetic data, antibody analyses and further molecular analyses. This unique combination of data enables researchers to identify risk factors for long-term symptoms caused by infections, to better understand different disease courses and to investigate the biological mechanisms underlying post-acute infection syndromes in a targeted manner,” reports Prof. Annette Peters, Chair of the Board of Directors of NAKO e.V. and Director of the Institute of Epidemiology at Helmholtz Munich.
Extensive molecular analyses
NAKO-PAIS also complements clinical trials by providing a population-based perspective. It includes people without a diagnosis, those with mild disease progression, and control groups without long-term symptoms. This enables researchers to compare potential risk and protective factors, as well as different disease trajectories.
A key component of molecular analysis is genome sequencing, supplemented by so-called serolomics techniques. These analyze antibody patterns against various pathogens and can thus provide evidence of previous infections. This enables researchers to better investigate which symptoms are associated with specific pathogens and which biological characteristics play a role in various post-infectious conditions.
Prof. Annette Peters at Helmholtz Munich is coordinating the project management and genetic analyses; Prof. Berit Lange at the Helmholtz Centre for Infection Research (HZI) is coordinating the serolomics procedures; and Dr Harald Grallert at Helmholtz Munich is coordinating the molecular data. Also involved are the German Cancer Research Centre (DKFZ) in the field of serolomics (Dr Tim Waterboer) and for data storage and provision (Prof. Oliver Stegle), and the University of Münster in the field of infectious disease epidemiology (Prof. André Karch).
The molecular analyses carried out as part of NAKO-PAIS are based on existing participants in the German National Cohort (NAKO). These participants were randomly selected at the start of the study in 2014 via their regional registration office and invited to take part in the examinations by their designated study center. It is therefore not possible for new participants to join the study at this stage.